Name: a "plug-and-display" nanoparticle vaccine platform based on outer membrane vesicles displaying sars-cov-2 receptor-binding domain
Uploaded: 2022-07-25T14:30:00
Description: Watch this Scientific Journal Video about A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain at JoVE.com

This work was supported by the Key Program of Chongqing Natural Science Foundation (No. cstc2020jcyj-zdxmX0027) and the Chinese National Natural Science Foundation Project (No. 31670936, 82041045).

1. Plasmid construction
<ol>
	<li>Insert DNA encoding SpyCatcher sequence (Supplementary File 1) into an ampicillin-resistant pThioHisA-ClyA plasmid (see Table of Materials) between the BamH I and Sal I sites to construct the plasmid pThioHisA ClyA-SC following a previously published report20.</li>
	<li>Ligate the synthesized SpyTag-RBD-Histag fusion gene (Supplementary File 1) into a pcDNA3.1 plasmid (see Table...

<ol>
	<li>Li, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bacterial+outer+membrane+vesicles+as+a+platform+for+biomedical+applications:+An+update.">Bacterial outer membrane vesicles as a platform for biomedical applications: An update.</a> Journal of Controlled Release. 323, 253-268 (2020).</li><li>Micoli, F., MacLennan, C. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Outer+membrane+vesicle+vaccines.">Outer membrane vesicle vaccines.</a> Seminars in Immunology. 50, 101433 (2020).</li><li>Toyofuku, M., Nomura, N., Eberl, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Types+and+origins+of+bacterial+membrane+vesicles.">Types and origins of bacterial membrane vesicles.</a> Nature Reviews Microbiology. 17 (1), 13-24 (2019).</li><li>Sartorio, M. G., Pardue, E. J., Feldman, M. F., Haurat, M. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bacterial+outer+membrane+vesicles:+From+discovery+to+applications.">Bacterial outer membrane vesicles: From discovery to applications.</a> Annual Review of Microbiology. 75, 609-630 (2021).</li><li>Kaparakis-Liaskos, M., Ferrero, R. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immune+modulation+by+bacterial+outer+membrane+vesicles.">Immune modulation by bacterial outer membrane vesicles.</a> Nature Reviews Immunology. 15 (6), 375-387 (2015).</li><li>Petousis-Harris, H., Radcliff, F. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Exploitation+of+Neisseria+meningitidis+group+B+OMV+vaccines+against+N-gonorrhoeae+to+inform+the+development+and+deployment+of+effective+gonorrhea+vaccines.">Exploitation of Neisseria meningitidis group B OMV vaccines against N-gonorrhoeae to inform the development and deployment of effective gonorrhea vaccines.</a> Frontiers in Immunology. 10, 683 (2019).</li><li>Gnopo, Y. M. D., Watkins, H. C., Stevenson, T. C., DeLisa, M. P., Putnam, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Designer+outer+membrane+vesicles+as+immunomodulatory+systems+-+Reprogramming+bacteria+for+vaccine+delivery.">Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.</a> Advanced Drug Delivery Reviews. 114, 132-142 (2017).</li><li>Zhang, Y. X., Fang, Z. Y., Li, R. Z., Huang, X. T., Liu, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Design+of+outer+membrane+vesicles+as+cancer+vaccines:+A+new+toolkit+for+cancer+therapy.">Design of outer membrane vesicles as cancer vaccines: A new toolkit for cancer therapy.</a> Cancers. 11 (9), 1314 (2019).</li><li>Berleman, J., Auer, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+role+of+bacterial+outer+membrane+vesicles+for+intra-+and+interspecies+delivery.">The role of bacterial outer membrane vesicles for intra- and interspecies delivery.</a> Environmental Microbiology. 15 (2), 347-354 (2013).</li><li>Huang, W. L., Meng, L. X., Chen, Y., Dong, Z. Q., Peng, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bacterial+outer+membrane+vesicles+as+potential+biological+nanomaterials+for+antibacterial+therapy.">Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy.</a> Acta Biomaterialia. 140, 102-115 (2022).</li><li>Hoffmann, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=SARS-CoV-2+cell+entry+depends+on+ACE2+and+TMPRSS2+and+is+blocked+by+a+clinically+proven+protease+inhibitor.">SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.</a> Cell. 181 (2), 271-280 (2020).</li><li>Robbiani, D. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Convergent+antibody+responses+to+SARS-CoV-2+in+convalescent+individuals.">Convergent antibody responses to SARS-CoV-2 in convalescent individuals.</a> Nature. 584 (7821), 437-442 (2020).</li><li>Wang, M. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=SARS-CoV-2:+Structure,+Biology,+and+Structure-Based+Therapeutics+Development.">SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development.</a> Frontiers in Cellular and Infection Microbiology. 10, 587269 (2020).</li><li>Yang, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Safety+and+immunogenicity+of+a+recombinant+tandem-repeat+dimeric+RBD-based+protein+subunit+vaccine+(ZF2001)+against+COVID-19+in+adults:+Two+randomised,+double-blind,+placebo-controlled,+phase+1+and+2+trials.">Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.</a> The Lancet Infectious Disease. 21 (8), 1107-1119 (2021).</li><li>Wang, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=mRNA+vaccine-elicited+antibodies+to+SARS-CoV-2+and+circulating+variants.">mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.</a> Nature. 592 (7855), 616-622 (2021).</li><li>Amanat, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=SARS-CoV-2+mRNA+vaccination+induces+functionally+diverse+antibodies+to+NTD,+RBD,+and+S2.">SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.</a> Cell. 184 (15), 3936-3948 (2021).</li><li>Tan, H. X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunogenicity+of+prime-boost+protein+subunit+vaccine+strategies+against+SARS-CoV-2+in+mice+and+macaques.">Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.</a> Nature Communication. 12 (1), 1403 (2021).</li><li>Thapa, H. B., Mueller, A. M., Camilli, A., Schild, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=An+intranasal+vaccine+based+on+outer+membrane+vesicles+against+SARS-CoV-2.">An intranasal vaccine based on outer membrane vesicles against SARS-CoV-2.</a> Frontiers in Microbiology. 12, 752739 (2021).</li><li>Ma, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Nanoparticle+vaccines+based+on+the+receptor+binding+domain+(RBD)+and+heptad+repeat+(HR)+of+SARS-CoV-2+elicit+robust+protective+immune+responses.">Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses.</a> Immunity. 53 (6), 1315-1330 (2020).</li><li>Yang, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RBD-modified+bacterial+vesicles+elicited+potential+protective+immunity+against+SARS-CoV-2.">RBD-modified bacterial vesicles elicited potential protective immunity against SARS-CoV-2.</a> Nano Letters. 21 (14), 5920-5930 (2021).</li><li>Rhinesmith, T., Killinger, B. A., Sharma, A., Moszczynska, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Multimer-PAGE:+A+method+for+capturing+and+resolving+protein+complexes+in+biological+samples.">Multimer-PAGE: A method for capturing and resolving protein complexes in biological samples.</a> Journal of Visualized Experiments. (123), e55341 (2017).</li><li>Arslan, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Determining+total+protein+and+bioactive+protein+concentrations+in+bovine+colostrum.">Determining total protein and bioactive protein concentrations in bovine colostrum.</a> Journal of Visualized Experiments. (178), e63001 (2021).</li><li>Alves, N. J., Turner, K. B., Walper, S. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Directed+protein+packaging+within+outer+membrane+vesicles+from+Escherichia+coli:+Design,+production+and+purification.">Directed protein packaging within outer membrane vesicles from Escherichia coli: Design, production and purification.</a> Journal of Visualized Experiments. (117), e54458 (2016).</li><li>Kim, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genomic+and+transcriptomic+landscape+of+Escherichia+coli+BL21(DE3).">Genomic and transcriptomic landscape of Escherichia coli BL21(DE3).</a> Nucleic Acids Research. 45 (9), 5285-5293 (2017).</li><li>Daleke-Schermerhorn, M. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Decoration+of+outer+membrane+vesicles+with+multiple+antigens+by+using+an+autotransporter+approach.">Decoration of outer membrane vesicles with multiple antigens by using an autotransporter approach.</a> Applied and Environmental Microbiology. 80 (18), 5854-5865 (2014).</li><li>Kuipers, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Salmonella+outer+membrane+vesicles+displaying+high+densities+of+pneumococcal+antigen+at+the+surface+offer+protection+against+colonization.">Salmonella outer membrane vesicles displaying high densities of pneumococcal antigen at the surface offer protection against colonization.</a> Vaccine. 33 (17), 2022-2029 (2015).</li><li>Veggiani, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Programmable+polyproteams+built+using+twin+peptide+superglues.">Programmable polyproteams built using twin peptide superglues.</a> Proceedings of the National Academy of Sciences of the United States of America. 113 (5), 1202-1207 (2016).</li><li>Saunders, K. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Neutralizing+antibody+vaccine+for+pandemic+and+pre-emergent+coronaviruses.">Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.</a> Nature. 594, 553-559 (2021).</li><li>van Saparoea, H. B. V., Houben, D., Kuijl, C., Luirink, J., Jong, W. S. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Combining+protein+ligation+systems+to+expand+the+functionality+of+semi-synthetic+outer+membrane+vesicle+nanoparticles.">Combining protein ligation systems to expand the functionality of semi-synthetic outer membrane vesicle nanoparticles.</a> Frontiers in Microbiology. 11, 890 (2020).</li><li>Needham, B. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Modulating+the+innate+immune+response+by+combinatorial+engineering+of+endotoxin.">Modulating the innate immune response by combinatorial engineering of endotoxin.</a> Proceedings of the National Academy of Sciences of the United States of America. 110 (4), 1464-1469 (2013).</li><li>Zanella, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Proteome-minimized+outer+membrane+vesicles+from+Escherichia+coli+as+a+generalized+vaccine+platform.">Proteome-minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform.</a> Journal of Extracellular Vesicles. 10 (4), 12066 (2021).</li><li>Wang, J. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Truncating+the+structure+of+lipopolysaccharide+in+Escherichia+coli+can+effectively+improve+poly-3-hydroxybutyrate+production.">Truncating the structure of lipopolysaccharide in Escherichia coli can effectively improve poly-3-hydroxybutyrate production.</a> ACS Synthetic Biology. 9 (5), 1201-1215 (2020).</li><li>Liu, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Outer+membrane+vesicles+from+flagellin-deficient+Salmonella+enterica+serovar+Typhimurium+induce+cross-reactive+immunity+and+provide+cross-protection+against+heterologous+Salmonella+challenge.">Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge.</a> Scientific Reports. 6, 34776 (2016).</li><li>Balhuizen, M. D., Veldhuizen, E. J. A., Haagsman, H. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Outer+membrane+vesicle+induction+and+isolation+for+vaccine+development.">Outer membrane vesicle induction and isolation for vaccine development.</a> Frontiers in Microbiology. 12, 629090 (2021).</li><li>Hua, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+novel+immunomodulator+delivery+platform+based+on+bacterial+biomimetic+vesicles+for+enhanced+antitumor+immunity.">A novel immunomodulator delivery platform based on bacterial biomimetic vesicles for enhanced antitumor immunity.</a> Advanced Materials. 33 (43), 2103923 (2021).</li></ol>

To create a &#34;Plug-and-Display&#34; nanoparticle vaccine platform, SC-fused ClyA was expressed in BL21(DE3) strains, which is one of the most widely used models for recombinant protein production because of its advantages in protein expression24, so that there would be enough SC fragment displaying on the surface of the OMVs during the process of bacteria proliferation. At the same time, an ST-fused target antigen was prepared for the chemical coupling between the antigens and OMVs. This experi...

As a potential vaccine platform, outer membrane vesicles (OMVs) have attracted more and more attention in recent years1,2. OMVs, mainly secreted naturally by gram-negative bacteria3, are spherical nanoscale particles composed of a lipid bilayer, usually in the size of 20-300 nm4. OMVs contain various parental bacterial components, including bacterial antigens and pathogen-associated molecular patterns (PAMPs), which serve as solid immune potentiators5. Benefiting from their unique components, natural vesicle structure, and great genetic engineering modification sites, OMVs have been developed for use in many biomedical fields, including bacterial vaccines6, adjuvants7, cancer immunotherapy drugs8, drug delivery vectors9, and anti-bacterial adhesives10.
The SARS-CoV-2 pandemic, which has spread worldwide since 2020, has taken a heavy toll on global society. The receptor-binding domain (RBD) in spike protein (S protein) can bind with human angiotensin-converting enzyme 2 (ACE2), which then mediates the entry of the virus into the cell11,12,13. Thus, RBD seems to be a prime target for vaccine discovery14,15,16. However, monomeric RBD is poorly immunogenic, and its small molecular weight makes it difficult for the immune system to recognize, so adjuvants are often required17.
In order to increase the immunogenicity of RBD, OMVs displaying polyvalent RBDs were constructed. Existing studies using OMV to display RBD usually fuse RBD with OMV to be expressed in bacteria18. However, RBD is a virus-derived protein, and prokaryotic expression is likely to affect its activity. To solve this problem, the SpyTag (ST)/SpyCatcher (SC) system, derived from Streptococcus pyogenes, was used to form a covalent isopeptide with OMV and RBD in a conventional buffer system19. The SC domain was expressed with Cytolysin A (ClyA) as a fusion protein by bioengineered Escherichia coli, and ST was expressed with RBD via the HEK293F cellular expression system. OMV-SC and RBD-ST were mixed and incubated overnight. After purification by ultracentrifugation or size-exclusion chromatography (SEC), OMV-RBD was obtained.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Ampicillin sodium</td>
			<td>Sangon Biotech</td>
			<td>A610028</td>
			<td></td>
		</tr>
		<tr>
			<td>Automated cell counter</td>
			<td>Countstar</td>
			<td>BioTech</td>
			<td></td>
		</tr>
		<tr>
			<td>BCA protein quantification Kit</td>
			<td>cwbio</td>
			<td>cw0014s</td>
			<td></td>
		</tr>
		<tr>
			<td>ChemiDoc Touching Imaging System</td>
			<td>Bio-rad</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Danamic Light Scattering</td>
			<td>Malvern</td>
			<td>Zetasizer Nano S90</td>
			<td></td>
		</tr>
		<tr>
			<td>Electrophoresis apparatus</td>
			<td>Cavoy</td>
			<td>Power BV</td>
			<td></td>
		</tr>
		<tr>
			<td>EZ-Buffers H 10X TBST Buffer</td>
			<td>Sangon Biotech</td>
			<td>C520009</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat pAb to mouse IgG1</td>
			<td>Abcam</td>
			<td>ab97240</td>
			<td></td>
		</tr>
		<tr>
			<td>High speed freezing centrifuge</td>
			<td>Bioridge</td>
			<td>H2500R</td>
			<td></td>
		</tr>
		<tr>
			<td>His-Tag mouse mAb</td>
			<td>Cell signaling technology</td>
			<td>2366s</td>
			<td></td>
		</tr>
		<tr>
			<td>Imidazole</td>
			<td>Sangon Biotech</td>
			<td>A600277</td>
			<td></td>
		</tr>
		<tr>
			<td>Isopropyl beta-D-thiogalactopyranoside</td>
			<td>Sangon Biotech</td>
			<td>A600118</td>
			<td></td>
		</tr>
		<tr>
			<td>Ni-NTA His-Bind Superflow</td>
			<td>Qiagen</td>
			<td>70691</td>
			<td></td>
		</tr>
		<tr>
			<td>Non-fat powdered milk</td>
			<td>Sangon Biotech</td>
			<td>A600669</td>
			<td></td>
		</tr>
		<tr>
			<td>OPM-293 cell culture medium</td>
			<td>Opm biosciences</td>
			<td>81075-001</td>
			<td></td>
		</tr>
		<tr>
			<td>pcDNA3.1 RBD-ST plasmid</td>
			<td>Wuhan genecreat biological techenology</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Phosphate buffer saline</td>
			<td>ZSGB-bio</td>
			<td>ZLI-9061</td>
			<td></td>
		</tr>
		<tr>
			<td>Polyethylenimine Linear</td>
			<td>Polysciences</td>
			<td>23966-1</td>
			<td></td>
		</tr>
		<tr>
			<td>Prestained protein ladder</td>
			<td>Thermo</td>
			<td>26616</td>
			<td></td>
		</tr>
		<tr>
			<td>pThioHisA ClyA-SC plasmid</td>
			<td>Wuhan genecreat biological techenology</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>PVDF Western Blotting Membranes</td>
			<td>Roche</td>
			<td>03010040001</td>
			<td></td>
		</tr>
		<tr>
			<td>Quixstand benchtop systems (100 kD hollow fiber column)</td>
			<td>GE healthcare</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>SDS-PAGE loading buffer (5x)</td>
			<td>Beyotime</td>
			<td>P0015</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium chloride</td>
			<td>Sangon Biotech</td>
			<td>A100241</td>
			<td></td>
		</tr>
		<tr>
			<td>Supersignal west pico PLUS (enhanced chemiluminescence solution)</td>
			<td>Thermo</td>
			<td>34577</td>
			<td></td>
		</tr>
		<tr>
			<td>Suspension instrument</td>
			<td>Life Technology</td>
			<td>Hula Mixer</td>
			<td></td>
		</tr>
		<tr>
			<td>Transmission Electron Microscope</td>
			<td>Hitachi</td>
			<td>HT7800</td>
			<td></td>
		</tr>
		<tr>
			<td>Tryptone</td>
			<td>Oxoid</td>
			<td>LP0042B</td>
			<td></td>
		</tr>
		<tr>
			<td>Ultracentrifuge</td>
			<td>Beckman coulter</td>
			<td>XPN-100</td>
			<td></td>
		</tr>
		<tr>
			<td>Ultraviolet spectrophotometer</td>
			<td>Hitachi</td>
			<td>U-3900</td>
			<td></td>
		</tr>
		<tr>
			<td>Yeast extract</td>
			<td>Sangon Biotech</td>
			<td>A610961</td>
			<td></td>
		</tr>
	</tbody>
</table>

a "plug-and-display" nanoparticle vaccine platform based on outer membrane vesicles displaying sars-cov-2 receptor-binding domain

Biomimetic nanoparticles obtained from bacteria or viruses have attracted substantial interest in vaccine research and development. Outer membrane vesicles (OMVs) are mainly secreted by gram-negative bacteria during average growth, with a nano-sized diameter and self-adjuvant activity, which may be ideal for vaccine delivery. OMVs have functioned as a multifaceted delivery system for proteins, nucleic acids, and small molecules. To take full advantage of the biological characteristics of OMVs, bioengineered Escherichia coli-derived&#160;OMVs were utilized as a carrier and SARS-CoV-2 receptor-binding domain (RBD) as an antigen to construct a &#34;Plug-and-Display&#34; vaccine platform. The SpyCatcher (SC) and SpyTag (ST) domains in Streptococcus pyogenes were applied to conjugate OMVs and RBD. The Cytolysin A (ClyA) gene was translated with the SC gene as a fusion protein after plasmid transfection, leaving a reactive site on the surface of the OMVs. After mixing RBD-ST in a conventional buffer system overnight, covalent binding was formed between the OMVs and RBD. Thus, a multivalent-displaying OMV vaccine was achieved. By replacing with diverse antigens, the OMVs vaccine platform can efficiently display a variety of heterogeneous antigens, thereby potentially rapidly preventing infectious disease epidemics. This protocol describes a precise method for constructing the OMV vaccine platform, including production, purification, bioconjugation, and characterization.

The flowchart for this protocol is shown in Figure 1. This protocol could be a general approach to utilizing OMVs as a vaccine platform; one only needs to choose the appropriate expression systems based on the type of antigens.
Figure 2&#160;provides a feasible plasmid design scheme. The SC gene is connected with the ClyA gene via a flexible linker, while ST connects to the 5&#39; terminal of the RBD gene with a His-tag gene for purif...

Watch this Scientific Journal Video about A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain at JoVE.com

A &quot;Plug-And-Display&quot; Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

The present protocol describes the bioengineering of outer membrane vesicles to be a "Plug-and-Display" vaccine platform, including production, purification, bioconjugation, and characterization.

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Biomimetic nanoparticles obtained from bacteria or viruses have attracted substantial interest in vaccine research and development. Outer membrane ...

Nanoscience can effectively enhance the antigen-specific immune response after displaying antigens on the surface of The main advantage in this vaccine platform can achieve the go off plaque and display. In other words, the platform is able to display the variety of antigens in This method can also be applied to other biological nanoparticles to display engine to nano-sized carriers. To perform cytolysin A spy catheter transformation, start with adding five microliters of plasma solution to 50 microliters of BL 21 competent strain.Gently blow and let cool on ice for 30 minutes. Place the solution for 90 seconds in the water bath at 42 degrees Celsius, and then immediately put the mixed solution on ice for three minutes. Add 500 microliters of luria bertani medium to the bacterial suspension and after mixing culture at 220 rotations per minute at 37 degrees Celsius for one hour.Next, plate all the transformation luria bertani agar plate containing ampicillin and culture overnight at 37 degrees Celsius. For OMV spycatcher production, start by isolating a single colony from the plate to 20 milliliters of luria bertani medium and culture overnight at 220 rotations per minute at 37 degrees Celsius. Incubate the bacterial solution into a two liter medium and culture at 220 rotations per minute at 37 degree Celsius for five hours until the logarithmic growth stage is reached.Add isopropyl beta D-IPTG to make the final concentration of the bacterial solution to be 0.5 millimolar and then culture overnight at 220 rotations per minute at 25 degree Celsius. Next, perform OMV spycatcher purification. Start with centri fusing the bacterial solution.Filter the supernatant with a 0.22 micrometer membrane filter, then concentrate it using a hollow fiber column. Filter the concentrate through a 0.22 micrometer membrane filter, then centri fuse it at 150, 000 times G at four degree Celsius for two hours using an ultra centri fuse, and discard the supernatant with a pipette. Re-suspend the precipitation with PBS, and store it at minus 80 degrees Celsius.To perform RBD spytag transfection, begin with selecting an appropriate eukaryotic expression system and culture the cells overnight at 130 rotations per minute at 37 degrees Celsius after recovery. Add 20 microliters HEK 293F of cell solution into the automated cell counter. Record the number of cells, adjust the concentration to one times 10 to the six cells per milliliter.And then culture the cells at 130 rotations per minute at 37 degrees Celsius for four hours. Filter RBD spy tag plasmid through a 0.22 micrometer membrane filter and add 300 micrograms of plasmids into the cell culture medium until the final volume is 10 milliliters. Shake for 10 seconds.Heat PEI to 65 degrees Celsius in the water bath. Mix 0.7 milliliters of PEI with 9.3 milliliters of cell culture medium, and shake intermittently for 10 seconds. Add plasmid solution to the PEI solution.Shake the mixture intermittently for 10 seconds, and incubate it at 37 degrees Celsius for 15 minutes. Add the mixture to 280 milliliters of cell culture medium, and culture at 130 rotations per minute at 37 degrees Celsius for five days. Next, perform RBD spytag purification.Start with centri fusing the cells at 6, 000 times G at 25 degrees Celsius for 20 minutes, and use a pipette to collect the supernatant. Fill the column with two milliliters of nickel NTA agarose and wash it three times with PBS. Add imidazole into the cell supernatant to make the final concentration of 20 millimolar, and load the cell supernatant.Add three column volumes of PBS containing 20 millimolar of imidazole for washing, and collect the washing fraction. Gradient elute with three column volumes of PBS containing low to high concentrations of imidazole elute twice for each concentration. To determine the protein concentration by the BCA method, serially dilute the standard BSA protein solution from two to 0.0625 milligrams per milliliter, dilute the purified OMV spycatcher and RBD spy tag 10 times.Then mix BCA working solutions A and B at a ratio of 50 to one. Add diluted protein solution, and mix with BCA working solution. Incubate at 37 degrees for 30 minutes.Measure the absorbance at 562 nanometers of each well, and calculate the protein concentration from the standard curve. To perform bioconjugation of OMV spycatcher and RBD spy tag, mix OMV spycatcher and RBD spytag and PBS at a 40 to one ratio. Vertically rotate to blend the mixture overnight at 15 rotations per minute at four degrees Celsius.Perform purification of OMV RBD using PBS solution using a procedure similar to OMV spycatcher purification. The plasma design scheme shows that the spycatcher gene is connected with the cly A gene via flexible linker while the spytag connects to the five prime terminal of the RBD gene with a hys tag gene for purification and verification. After ultracentrifugation, almost all the un-reacted RBD spytag remained in the supernatant.The second ultracentrifugation did not provide a further significant advantage over the first time. The z average hydrodynamic diameter of OMV spycatcher was 133 nanometers while it was 152.6 nanometers for OMV-RBD. These differences may be because RBD increases OMV particle size after intensive displaying.The results of TEM are consistent with the particle size distribution obtained from the DLS results. Rotation for blending the mixture is very important. The efficiency of reaction can be much lower without rotation.

a-plug-display-nanoparticle-vaccine-platform-based-on-outer-membrane

Research

JoVE Journal

Bioengineering

Stretching Micropatterned Cells on a PDMS Membrane

Mechanical forces exerted on cells and/or tissues play a major role in numerous processes. We have developed a device to stretch cells plated on a PolyDiMethylSiloxane (PDMS) membrane, compatible with imaging. This technique is reproducible and versatile. The PDMS membrane can be micropatterned in order to confine cells or tissues to a specific geometry. The first step is to print micropatterns onto the PDMS membrane with a deep UV technique. The PDMS membrane is then mounted on a mechanical stretcher. A chamber is bound on top of the membrane with biocompatible grease to allow gliding during the stretch. The cells are seeded and allowed to spread for several hours on the micropatterns. The sample can be stretched and unstretched multiple times with the use of a micrometric screw. It takes less than a minute to apply the stretch to its full extent (around 30%). The technique presented here does not include a motorized device, which is necessary for applying repeated stretch cycles quickly and/or computer controlled stretching, but this can be implemented. Stretching of cells or tissue can be of interest for questions related to cell forces, cell response to mechanical stress or tissue morphogenesis. This video presentation will show how to avoid typical problems that might arise when doing this type of seemingly simple experiment.

This manuscript presents a technique to apply or release forces on adherent cells or tissues using unidirectional stretching.

Mechanical forces exerted on cells and/or tissues  play a major role in numerous processes. We have developed a device to stretch  cells plated on a ...

Paper-based Devices for Isolation and Characterization of Extracellular Vesicles

Extracellular vesicles (EVs), membranous particles released from various types of cells, hold a great potential for clinical applications. They contain nucleic acid and protein cargo and are increasingly recognized as a means of intercellular communication utilized by both eukaryote and prokaryote cells. However, due to their small size, current protocols for isolation of EVs are often time consuming, cumbersome, and require large sample volumes and expensive equipment, such as an ultracentrifuge. To address these limitations, we developed a paper-based immunoaffinity platform for separating subgroups of EVs that is easy, efficient, and requires sample volumes as low as 10 &#956;l. Biological samples can be pipetted directly onto paper test zones that have been chemically modified with capture molecules that have high affinity to specific EV surface markers. We validate the assay by using scanning electron microscopy (SEM), paper-based enzyme-linked immunosorbent assays (P-ELISA), and transcriptome analysis. These paper-based devices will enable the study of EVs in the clinic and the research setting to help advance our understanding of EV functions in health and disease.

This protocol details a method to isolate extracellular vesicles (EVs), small membranous particles released from cells, from as little as 10 &#956;l serum samples. This approach circumvents the need for ultracentrifugation, requires only a few minutes of assay time, and enables the isolation of EVs from samples of limited volumes.

Extracellular vesicles (EVs), membranous particles released from various types of cells, hold a great potential for clinical applications. They contain ...

Fabrication of a Functionalized Magnetic Bacterial Nanocellulose with Iron Oxide Nanoparticles

In this study, bacterial nanocellulose (BNC) produced by the bacteria Gluconacetobacter xylinus is synthesized and impregnated in situ with iron oxide nanoparticles (IONP) (Fe3O4) to yield a magnetic bacterial nanocellulose (MBNC). The synthesis of MBNC is a precise and specifically designed multi-step process. Briefly, bacterial nanocellulose (BNC) pellicles are formed from preserved G. xylinus strain according to our experimental requirements of size and morphology. A solution of iron(III) chloride hexahydrate (FeCl3&#183;6H2O) and iron(II) chloride tetrahydrate (FeCl2&#183;4H2O) with a 2:1 molar ratio is prepared and diluted in deoxygenated high purity water. A BNC pellicle is then introduced in the vessel with the reactants. This mixture is stirred and heated at 80 &#176;C in a silicon oil bath and ammonium hydroxide (14%) is then added by dropping to precipitate the ferrous ions into the BNC mesh. This last step allows forming in situ magnetite nanoparticles (Fe3O4) inside the bacterial nanocellulose mesh to confer magnetic properties to BNC pellicle. A toxicological assay was used to evaluate the biocompatibility of the BNC-IONP pellicle. Polyethylene glycol (PEG) was used to cover the IONPs in order to improve their biocompatibility. Scanning electron microscopy (SEM) images showed that the IONP were located preferentially in the fibril interlacing spaces of the BNC matrix, but some of them were also found along the BNC ribbons. Magnetic force microscope measurements performed on the MBNC detected the presence magnetic domains with high and weak intensity magnetic field, confirming the magnetic nature of the MBNC pellicle. Young&#39;s modulus values obtained in this work are also in a reasonable agreement with those reported for several blood vessels in previous studies.

Here, we present a protocol to make a bacterial nanocellulose (BNC) magnetic for applications in damaged blood vessel reconstruction. The BNC was synthesized by G. xylinus strain. On the other hand, magnetization of the BNC was realized through in situ precipitation of Fe2+ and Fe3+ ferrous ions inside the BNC mesh.

In this study, bacterial nanocellulose (BNC) produced by the bacteria Gluconacetobacter xylinus is synthesized and impregnated in situ with iron oxide ...

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

The controlled delivery of drug/imaging agents to cells is critical for the development of therapeutics and for the study of cellular signaling processes. Recently, nanoparticles (NPs) have shown significant promise in the development of such delivery systems. Here, a liquid crystal NP (LCNP)-based delivery system has been employed for the controlled delivery of a water-insoluble dye, 3,3&#8242;-dioctadecyloxacarbocyanine perchlorate (DiO), from within the NP core to the hydrophobic region of a plasma membrane bilayer. During the synthesis of the NPs, the dye was efficiently incorporated into the hydrophobic LCNP core, as confirmed by multiple spectroscopic analyses. Conjugation of a PEGylated cholesterol derivative to the NP surface (DiO-LCNP-PEG-Chol) enabled the binding of the dye-loaded NPs to the plasma membrane in HEK 293T/17 cells. Time-resolved laser scanning confocal microscopy and F&#246;rster resonance energy transfer (FRET) imaging confirmed the passive efflux of DiO from the LCNP core and its insertion into the plasma membrane bilayer. Finally, the delivery of DiO as a LCNP-PEG-Chol attenuated the cytotoxicity of DiO; the NP form of DiO exhibited ~30-40% less toxicity compared to DiOfree delivered from bulk solution. This approach demonstrates the utility of the LCNP platform as an efficient modality for the membrane-specific delivery and modulation of hydrophobic molecular cargos.

A liquid crystal nanoparticle (LCNP) nanocarrier is exploited as a vehicle for the controlled delivery of a hydrophobic cargo to the plasma membrane of living cells.

The controlled delivery of drug/imaging agents to cells is critical for the development of therapeutics and for the study of cellular signaling processes. ...

Dry Film Photoresist-based Electrochemical Microfluidic Biosensor Platform: Device Fabrication, On-chip Assay Preparation, and System Operation

In recent years, biomarker diagnostics became an indispensable tool for the diagnosis of human disease, especially for the point-of-care diagnostics. An easy-to-use and low-cost sensor platform is highly desired to measure various types of analytes (e.g., biomarkers, hormones, and drugs) quantitatively and specifically. For this reason, dry film photoresist technology - enabling cheap, facile, and high-throughput fabrication - was used to manufacture the microfluidic biosensor presented here. Depending on the bioassay used afterwards, the versatile platform is capable of detecting various types of biomolecules. For the fabrication of the device, platinum electrodes are structured on a flexible polyimide (PI) foil in the only clean-room process step. The PI foil serves as a substrate for the electrodes, which are insulated with an epoxy-based photoresist. The microfluidic channel is subsequently generated by the development and lamination of dry film photoresist (DFR) foils onto the PI wafer. By using a hydrophobic stopping barrier in the channel, the channel is separated into two specific areas: an immobilization section for the enzyme-linked assay and an electrochemical measurement cell for the amperometric signal readout.
The on-chip bioassay immobilization is performed by the adsorption of the biomolecules to the channel surface. The glucose oxidase enzyme is used as a transducer for electrochemical signal generation. In the presence of the substrate, glucose, hydrogen peroxide is produced, which is detected at the platinum working electrode. The stop-flow technique is applied to obtain signal amplification along with rapid detection. Different biomolecules can quantitatively be measured by means of the introduced microfluidic system, giving an indication of different types of diseases, or, in regard to therapeutic drug monitoring, facilitating a personalized therapy.

A microfluidic biosensor platform was designed and fabricated using low-cost dry film photoresist technology for the rapid and sensitive quantification of various analytes. This single-use system allows for the electrochemical readout of on-chip-immobilized enzyme-linked assays by means of the stop-flow technique.

In recent years, biomarker diagnostics became an indispensable tool for the diagnosis of human disease, especially for the point-of-care diagnostics. An ...

Lab-on-a-CD Platform for Generating Multicellular Three-dimensional Spheroids

A three-dimensional spheroid cell culture can obtain more useful results in cell experiments because it can better simulate cell microenvironments of the living body than two-dimensional cell culture. In this study, we fabricated an electrical motor-driven lab-on-a-CD (compact disc) platform, called a centrifugal microfluidic-based spheroid (CMS) culture system, to create three-dimensional (3D) cell spheroids implementing high centrifugal force. This device can vary rotation speeds to generate gravity conditions from 1 x g to 521 x g. The CMS system is 6 cm in diameter, has one hundred 400 &#956;m microwells, and is made by molding with polydimethylsiloxane in a polycarbonate mold premade by a computer numerical control machine. A barrier wall at the channel entrance of the CMS system uses centrifugal force to spread cells evenly inside the chip. At the end of the channel, there is a slide region that allows the cells to enter the microwells. As a demonstration, spheroids were generated by monoculture and coculture of human adipose-derived stem cells and human lung fibroblasts under high gravity conditions using the system. The CMS system used a simple operation scheme to produce coculture spheroids of various structures of concentric, Janus, and sandwich. The CMS system will be useful in cell biology and tissue engineering studies that require spheroids and organoid culture of single or multiple cell types.

We present a motor-powered centrifugal microfluidic device that can cultivate cell spheroids. Using this device, spheroids of single or multiple cell types could be easily cocultured under high gravity conditions.

A three-dimensional spheroid cell culture can obtain more useful results in cell experiments because it can better simulate cell microenvironments of the ...

A Lab-On-A-Chip Platform for Stimulating Osteocyte Mechanotransduction and Analyzing Functional Outcomes of Bone Remodeling

Bone remodeling is a tightly regulated process that is required for skeletal growth and repair as well as adapting to changes in the mechanical environment. During this process, mechanosensitive osteocytes regulate the opposing responses between the catabolic osteoclasts and anabolic osteoblasts. To better understand the highly intricate signaling pathways that regulate this process, our lab has developed a foundationary lab-on-a-chip (LOC) platform for analyzing functional outcomes (formation and resorption) of bone remodeling within a small scale system. As bone remodeling is a lengthy process that occurs on the order of weeks to months, we developed long-term cell culturing protocols within the system. Osteoblasts and osteoclasts were grown on functional activity substrates within the LOC and maintained for up to seven weeks. Afterward, chips were disassembled to allow for the quantification of bone formation and resorption. Additionally, we have designed a 3D printed mechanical loading device that pairs with the LOC platform and can be used to induce osteocyte mechanotransduction by deforming the cellular matrix. We have optimized cell culturing protocols for osteocytes, osteoblasts, and osteoclasts within the LOC platform and have addressed concerns of sterility and cytotoxicity. Here, we present the protocols for fabricating and sterilizing the LOC, seeding cells on functional substrates, inducing mechanical load, and disassembling the LOC to quantify endpoint results. We believe that these techniques lay the groundwork for developing a true organ-on-a-chip for bone remodeling.

Here, we present protocols for analyzing bone remodeling within a lab-on-a-chip platform. A 3D printed mechanical loading device can be paired with the platform to induce osteocyte mechanostransduction by deforming the cellular matrix. The platform can also be used to quantify bone remodeling functional outcomes from osteoclasts and osteoblasts (resorption/formation).

Bone remodeling is a tightly regulated process that is required for skeletal growth and repair as well as adapting to changes in the mechanical ...

Generation of a Simplified Three-Dimensional Skin-on-a-chip Model in a Micromachined Microfluidic Platform

This work presents a new, cost-effective, and reliable microfluidic platform with the potential to generate complex multilayered tissues. As a proof of concept, a simplified and undifferentiated human skin containing a dermal (stromal) and an epidermal (epithelial) compartment has been modelled. To accomplish this, a versatile and robust, vinyl-based device divided into two chambers has been developed, overcoming some of the drawbacks present in microfluidic devices based on polydimethylsiloxane (PDMS) for biomedical applications, such as the use of expensive and specialized equipment or the absorption of small, hydrophobic molecules and proteins. Moreover, a new method based on parallel flow was developed, enabling the in situ deposition of both the dermal and epidermal compartments. The skin construct consists of a fibrin matrix containing human primary fibroblasts and a monolayer of immortalized keratinocytes seeded on top, which is subsequently maintained under dynamic culture conditions. This new microfluidic platform opens the possibility to model human skin diseases and extrapolate the method to generate other complex tissues.

Here, we present a protocol to generate a three-dimensional simplified and undifferentiated skin model using a micromachined microfluidic platform. A parallel flow approach allows the in situ deposition of a dermal compartment for the seeding of epithelial cells on top, all controlled by syringe pumps.

This work presents a new, cost-effective, and reliable microfluidic platform with the potential to generate complex multilayered tissues. As a proof of ...

Size Exclusion Chromatography to Analyze Bacterial Outer Membrane Vesicle Heterogeneity

The cell wall of Gram-negative bacteria consists of an inner (cytoplasmic) and outer membrane (OM), separated by a thin peptidoglycan layer. Throughout growth, the outer membrane can bleb to form spherical outer membrane vesicles (OMVs). These OMVs are involved in numerous cellular functions including cargo delivery to host cells and communication with bacterial cells. Recently, the therapeutic potential of OMVs has begun to be explored, including their use as vaccines and drug delivery vehicles. Although OMVs are derived from the OM, it has long been appreciated that the lipid and protein cargo of the OMV differs, often significantly, from that of the OM. More recently, evidence that bacteria can release multiple types of OMVs has been discovered, and evidence exists that size can impact the mechanism of their uptake by host cells. However, studies in this area are limited by difficulties in efficiently separating the heterogeneously sized OMVs. Density gradient centrifugation (DGC) has traditionally been used for this purpose; however, this technique is time-consuming and difficult to scale-up. Size exclusion chromatography (SEC), on the other hand, is less cumbersome and lends itself to the necessary future scale-up for therapeutic use of OMVs. Here, we describe a SEC approach that enables reproducible separation of heterogeneously sized vesicles, using as a test case, OMVs produced by Aggregatibacter actinomycetemcomitans, which range in diameter from less than 150 nm to greater than 350 nm. We demonstrate separation of &#34;large&#34; (350 nm) OMVs and &#34;small&#34; (&#60;150 nm) OMVs, verified by dynamic light scattering (DLS). We recommend SEC-based techniques over DGC-based techniques for separation of heterogeneously sized vesicles due to its ease of use, reproducibility (including user-to-user), and possibility for scale-up.

Bacterial vesicles play important roles in pathogenesis and have promising biotechnological applications. The heterogeneity of vesicles complicates analysis and use; therefore, a simple, reproducible method to separate varying sizes of vesicles is necessary. Here, we demonstrate the use of size exclusion chromatography to separate heterogeneous vesicles produced by Aggregatibacter actinomycetemcomitans.

The cell wall of Gram-negative bacteria consists of an inner (cytoplasmic) and outer membrane (OM), separated by a thin peptidoglycan layer. Throughout ...

Improving Reproducibility to Meet Minimal Information for Studies of Extracellular Vesicles 2018 Guidelines in Nanoparticle Tracking Analysis

Nanoparticle tracking analysis (NTA) has been one of several characterization methods used for extracellular vesicle (EV) research since 2006. Many consider that NTA instruments and their software packages can be easily utilized following minimal training and that size calibration is feasible in-house. As both NTA acquisition and software analysis constitute EV characterization, they are addressed in Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018). In addition, they have been monitored by Transparent Reporting and Centralizing Knowledge in Extracellular Vesicle Research (EV-TRACK) to improve the robustness of EV experiments (e.g., minimize experimental variation due to uncontrolled factors).
Despite efforts to encourage the reporting of methods and controls, many published research papers fail to report critical settings needed to reproduce the original NTA observations. Few papers report the NTA characterization of negative controls or diluents, evidently assuming that commercially available products, such as phosphate-buffered saline or ultrapure distilled water, are particulate-free. Similarly, positive controls or size standards are seldom reported by researchers to verify particle sizing. The Stokes-Einstein equation incorporates sample viscosity and temperature variables to determine particle displacement. Reporting the stable laser chamber temperature during the entire sample video collection is, therefore, an essential control measure for accurate replication. The filtration of samples or diluents is also not routinely reported, and if so, the specifics of the filter (manufacturer, membrane material, pore size) and storage conditions are seldom included. The International Society for Extracellular Vesicle (ISEV)&#39;s minimal standards of acceptable experimental detail should include a well-documented NTA protocol for the characterization of EVs. The following experiment provides evidence that an NTA analysis protocol needs to be established by the individual researcher and included in the methods of publications that use NTA characterization as one of the options to fulfill MISEV2018 requirements for single vesicle characterization.

Nanoparticle tracking analysis (NTA) is a widely used method to characterize extracellular vesicles. This paper highlights NTA experimental parameters and controls plus a uniform method of analysis and characterization of samples and diluents necessary to supplement the guidelines proposed by MISEV2018 and EV-TRACK for reproducibility between laboratories.

Nanoparticle tracking analysis (NTA) has been one of several characterization methods used for extracellular vesicle (EV) research since 2006. Many ...